Multidrug-Resistant Candida

Epidemiology, Molecular Mechanisms, and Treatment

Maiken Cavling Arendrup, Thomas F Patterson

Research output: Contribution to journalReview article

60 Citations (Scopus)

Abstract

Invasive Candida infections remain an important cause of morbidity and mortality, especially in hospitalized and immunocompromised or critically ill patients. A limited number of antifungal agents from only a few drug classes are available to treat patients with these serious infections. Resistance can be either intrinsic or acquired. Resistance mechanisms are not exchanged between Candida; thus, acquired resistance either emerges in response to an antifungal selection pressure in the individual patient or, more rarely, occur due to horizontal transmission of resistant strains between patients. Although multidrug resistance is uncommon, increasing reports of multidrug resistance to the azoles, echinocandins, and polyenes have occurred in several Candida species, most notably Candida glabrata and more recently Candida auris. Drivers are overall antifungal use, subtherapeutic drug levels at sites of infection/colonization, drug sequestration in the biofilm matrix, and, in the setting of outbreaks, suboptimal infection control. Moreover, recent research suggests that DNA mismatch repair gene mutations may facilitate acquisition of resistance mutations in C. glabrata specifically. Diagnosis of antifungal-resistant Candida infections is critical to the successful management of patients with these infections. Reduction of unnecessary use of antifungals via antifungal stewardship is critical to limit multidrug resistance emergence.

Original languageEnglish (US)
Pages (from-to)S445-S451
JournalThe Journal of infectious diseases
Volume216
Issue number3
DOIs
StatePublished - Aug 15 2017

Fingerprint

Molecular Epidemiology
Candida
Multiple Drug Resistance
Candida glabrata
Infection
Pharmaceutical Preparations
Echinocandins
Polyenes
Therapeutics
Azoles
Mutation
DNA Mismatch Repair
Antifungal Agents
Biofilms
Infection Control
Critical Illness
Disease Outbreaks
Morbidity
Pressure
Mortality

Keywords

  • amphotericin B
  • azole
  • Candida
  • Candida C. auris
  • Candida glabrate
  • echinocandin
  • fluconazole
  • multidrug resistance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Multidrug-Resistant Candida : Epidemiology, Molecular Mechanisms, and Treatment. / Arendrup, Maiken Cavling; Patterson, Thomas F.

In: The Journal of infectious diseases, Vol. 216, No. 3, 15.08.2017, p. S445-S451.

Research output: Contribution to journalReview article

@article{44168ab19fa343b4bf7db2280f4fc66e,
title = "Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment",
abstract = "Invasive Candida infections remain an important cause of morbidity and mortality, especially in hospitalized and immunocompromised or critically ill patients. A limited number of antifungal agents from only a few drug classes are available to treat patients with these serious infections. Resistance can be either intrinsic or acquired. Resistance mechanisms are not exchanged between Candida; thus, acquired resistance either emerges in response to an antifungal selection pressure in the individual patient or, more rarely, occur due to horizontal transmission of resistant strains between patients. Although multidrug resistance is uncommon, increasing reports of multidrug resistance to the azoles, echinocandins, and polyenes have occurred in several Candida species, most notably Candida glabrata and more recently Candida auris. Drivers are overall antifungal use, subtherapeutic drug levels at sites of infection/colonization, drug sequestration in the biofilm matrix, and, in the setting of outbreaks, suboptimal infection control. Moreover, recent research suggests that DNA mismatch repair gene mutations may facilitate acquisition of resistance mutations in C. glabrata specifically. Diagnosis of antifungal-resistant Candida infections is critical to the successful management of patients with these infections. Reduction of unnecessary use of antifungals via antifungal stewardship is critical to limit multidrug resistance emergence.",
keywords = "amphotericin B, azole, Candida, Candida C. auris, Candida glabrate, echinocandin, fluconazole, multidrug resistance",
author = "Arendrup, {Maiken Cavling} and Patterson, {Thomas F}",
year = "2017",
month = "8",
day = "15",
doi = "10.1093/infdis/jix131",
language = "English (US)",
volume = "216",
pages = "S445--S451",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Multidrug-Resistant Candida

T2 - Epidemiology, Molecular Mechanisms, and Treatment

AU - Arendrup, Maiken Cavling

AU - Patterson, Thomas F

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Invasive Candida infections remain an important cause of morbidity and mortality, especially in hospitalized and immunocompromised or critically ill patients. A limited number of antifungal agents from only a few drug classes are available to treat patients with these serious infections. Resistance can be either intrinsic or acquired. Resistance mechanisms are not exchanged between Candida; thus, acquired resistance either emerges in response to an antifungal selection pressure in the individual patient or, more rarely, occur due to horizontal transmission of resistant strains between patients. Although multidrug resistance is uncommon, increasing reports of multidrug resistance to the azoles, echinocandins, and polyenes have occurred in several Candida species, most notably Candida glabrata and more recently Candida auris. Drivers are overall antifungal use, subtherapeutic drug levels at sites of infection/colonization, drug sequestration in the biofilm matrix, and, in the setting of outbreaks, suboptimal infection control. Moreover, recent research suggests that DNA mismatch repair gene mutations may facilitate acquisition of resistance mutations in C. glabrata specifically. Diagnosis of antifungal-resistant Candida infections is critical to the successful management of patients with these infections. Reduction of unnecessary use of antifungals via antifungal stewardship is critical to limit multidrug resistance emergence.

AB - Invasive Candida infections remain an important cause of morbidity and mortality, especially in hospitalized and immunocompromised or critically ill patients. A limited number of antifungal agents from only a few drug classes are available to treat patients with these serious infections. Resistance can be either intrinsic or acquired. Resistance mechanisms are not exchanged between Candida; thus, acquired resistance either emerges in response to an antifungal selection pressure in the individual patient or, more rarely, occur due to horizontal transmission of resistant strains between patients. Although multidrug resistance is uncommon, increasing reports of multidrug resistance to the azoles, echinocandins, and polyenes have occurred in several Candida species, most notably Candida glabrata and more recently Candida auris. Drivers are overall antifungal use, subtherapeutic drug levels at sites of infection/colonization, drug sequestration in the biofilm matrix, and, in the setting of outbreaks, suboptimal infection control. Moreover, recent research suggests that DNA mismatch repair gene mutations may facilitate acquisition of resistance mutations in C. glabrata specifically. Diagnosis of antifungal-resistant Candida infections is critical to the successful management of patients with these infections. Reduction of unnecessary use of antifungals via antifungal stewardship is critical to limit multidrug resistance emergence.

KW - amphotericin B

KW - azole

KW - Candida

KW - Candida C. auris

KW - Candida glabrate

KW - echinocandin

KW - fluconazole

KW - multidrug resistance

UR - http://www.scopus.com/inward/record.url?scp=85029679275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029679275&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix131

DO - 10.1093/infdis/jix131

M3 - Review article

VL - 216

SP - S445-S451

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -